Azitra enters up to $20M equity line with Alumni Capital for clinical pipeline funding

Azitra, Inc.

Purchase Agreement with Alumni Capital LP for up to $20M of common stock and warrants over 20 months.
Azitra controls timing/amount of sales; purchase price at 90% of lowest VWAP during pricing period.
Each purchase includes warrants for 10% of shares at 130% of purchase price, exercisable for 5 years subject to shareholder approval.
Company must register resale of shares within 60 days; issuance exempt under Section 4(a)(2).
Proceeds to advance pipeline for Netherton Syndrome and EGFRi-associated rash.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.